What is common variable immunodeficiency (CVID) disease?

What is Common Variable Immunodeficiency (CVID)?

Common variable immunodeficiency (CVID) is a primary immunodeficiency of uncertain cause affecting approximately 1:30,000 persons, characterized by low serum IgG and IgA levels with impaired antibody responses, presenting primarily with recurrent bacterial respiratory infections but also with significant non-infectious complications including autoimmunity, lymphoproliferation, and malignancy. 1

Diagnostic Criteria

CVID should be diagnosed in male or female patients older than 4 years who have:

• Serum IgG level <450-500 mg/dL
• Serum IgA or IgM level <5th percentile (some authorities require both IgA and IgG to be low)
• Decreased ability to make specific antibodies
• Exclusion of other primary causes (X-linked agammaglobulinemia, X-linked lymphoproliferative disease) and secondary causes (medications, protein loss, B-cell lymphomas, bone marrow failure) 1

The diagnosis requires demonstrating impaired functional antibody responses to both protein and polysaccharide antigens, not just low immunoglobulin levels 1. No universally accepted consensus definition exists, reflecting the heterogeneous nature of this disorder 1.

Clinical Manifestations

Infectious Complications (Most Common)

Recurrent and chronic bacterial respiratory tract infections dominate the clinical picture:

• Otitis media, sinusitis, bronchitis, and pneumonias are most frequent 1
• Common pathogens: Encapsulated bacteria (nontypeable H. influenzae, S. pneumococcus) and atypical organisms (Mycoplasma, Ureaplasma) 1
• Recurrent/persistent viral respiratory infections, particularly rhinovirus 1

Pulmonary Complications (Major Cause of Morbidity/Mortality)

Noninfectious chronic pulmonary disease occurs in nearly 30% of patients and is associated with reduced survival:

• Bronchiectasis: 10-20% of patients, most common pulmonary complication 1
• Granulomatous and lymphocytic interstitial lung disease (GLILD): ~10% of patients, frequently accompanied by splenomegaly and diffuse adenopathy, associated with increased mortality 1
• Asthma-like presentation in 10-15% (usually without allergen-specific IgE) 1

Gastrointestinal Complications (20-25% of Patients)

Regular monitoring of GI status is essential:

• Chronic gastritis with/without pernicious anemia
• Lymphoid nodular hyperplasia, villous atrophy
• Inflammatory bowel disease and enteropathy
• Common infections: Giardiasis, C. jejuni, Salmonella, chronic viral enteritis (CMV, norovirus, parechovirus) 1

Liver involvement in ~40%:

• Elevated alkaline phosphatase most frequent abnormality
• Nodular regenerative hyperplasia leading to nonicteric portal hypertension is most common chronic liver disease 1

Autoimmune Complications (20% Overall Prevalence)

Vigilance for autoimmune disease must be maintained during follow-up:

• Autoimmune cytopenias (ITP, autoimmune hemolytic anemia) are most common, occurring in 11-12% of patients 1
• Broad spectrum of other autoimmune diseases possible 1

Lymphoproliferative and Malignant Complications

Ongoing vigilance for both nonmalignant and malignant lymphoproliferative disease is required 1. The presence of even one complication (cytopenias, lymphoproliferation, or enteropathy) increases mortality 11-fold 2.

Genetic Considerations

While CVID remains largely of unknown etiology, recent genetic discoveries include mutations in:

• PIK3CD (gain-of-function)
• PIK3R1 (loss- or gain-of-function)
• LRBA deficiency
• TNFS12 (TWEAK)
• Nuclear factor κB deficiency
• Protein kinase Cδ deficiency 1

However, known causative single gene defects account for only ~3% of cases 2, and most patients remain without identified genetic cause 3, 4.

Management Approach

Core Treatment Strategy

CVID should be managed aggressively with antimicrobials, IgG replacement, and careful attention to pulmonary status 1:

1. Lifelong immunoglobulin replacement therapy (preventative of majority of infections when given regularly) 3
2. Aggressive antimicrobial therapy for breakthrough infections
3. Antibiotic prophylaxis for patients with frequent sinusitis, otitis media, and bronchitis despite adequate IgG replacement—often needed for months, years, or permanently 1

Monitoring Requirements

Regular systematic monitoring is essential:

• Pulmonary status: Aggressive monitoring given association with reduced survival 1
• Gastrointestinal function: Regular assessment 1
• Autoimmune complications: Ongoing vigilance 1
• Lymphoproliferative/malignant disease: Continuous monitoring 1

Advanced Interventions

Stem cell transplantation can be considered for patients with malignancy or severe organ damage (though experience is very limited) 1. Lung transplantation should be considered for life-threatening chronic lung disease 1.

Critical Pitfalls

• Diagnostic delay is common (5-8 years after first symptoms) due to heterogeneous clinical presentation 5
• Even with adequate IgG replacement preventing invasive infections, many patients continue having recurrent sinusitis, otitis media, and bronchitis 1
• Late-onset combined immunodeficiency: Up to 9% develop sudden onset of opportunistic infections, often with CD4 <200 cells/mL, resembling Good syndrome without thymoma 1
• Non-infectious manifestations (autoimmune, lymphoproliferative, pulmonary) now pose the greatest therapeutic challenge and drive mortality 6